Interferon-alpha-2b transdermal - IDEA AG
Alternative Names: IDEA-032Latest Information Update: 02 Oct 2021
At a glance
- Originator IDEA
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Actinic keratosis; Hepatitis C
Most Recent Events
- 31 Dec 2005 No development reported - Phase-I for Actinic keratosis in Germany (Transdermal)
- 31 Dec 2005 No development reported - Phase-I for Hepatitis C treatment in Germany (Transdermal)
- 31 Oct 2001 Phase-I clinical trials in Actinic keratosis in Germany (Transdermal)